Is Adaptive Biotechnologies Corp (ADPT) a risky stock?
As of July 31, 2026, Clavix grades Adaptive Biotechnologies Corp (ADPT) C for risk, a composite score of 60 out of 100 on an A+ to F scale, which puts ADPT in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 31, 2026. Clavix regrades every trading day.
The five risk dimensions behind ADPT's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how ADPT scores on each, as of July 31, 2026.
What's moving ADPT's risk right now
Company-specific signals Clavix flags behind ADPT's current grade, drawn from recent news and filings as of July 31, 2026.
Adaptive's MRD business grew 49% in Q2 2026 (excluding milestones), and the company raised its full-year revenue outlook. Quarterly results also topped estimates on both earnings (+23%) and revenue (+8%).
Adaptive's minimal residual disease unit sped up in Q2 2026 with higher revenue, and the company also reported better margins and a higher full-year revenue outlook as it moves toward separating its Immune Medicine business.
A discounted cash flow model suggests Adaptive's shares trade about 22% below their estimated fair value, while the stock has delivered strong total returns over the past three years. Other valuation measures are sending mixed signals.
Recent ADPT news
The latest headlines Clavix ingested for Adaptive Biotechnologies Corp, newest first. These feed the news-sentiment dimension of ADPT's grade.
What a C grade means
On the Clavix A+ to F scale, ADPT's composite of 60 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell ADPT or any security. Grades are risk indicators, not predictions of return. Data may be delayed.